Sartorius and LFB Biomanufacturing have announced an expansion of their collaboration with the aim of offering biopharmaceutical clients a comprehensive cell-line development (CLD) to first batch of GMP drug substance service.
The collaboration is designed to simplify and accelerate the path to the clinic. Building on their successful collaboration launched in March 2024, this step will combine Sartorius expertise in CLD and master cell bank manufacturing with capabilities from LFB Biomanufacturing, including upstream and downstream process development, analytical development and testing, and GMP drug substance manufacturing.
Together, the collaboration enables Sartorius and LFB Biomanufacturing to gain access to each other’s respective platforms and technologies to offer a single path to the clinics.
France-based LFB Biomanufacturing is a recognised contract development and manufacturing organisation (CDMO) with extensive experience developing therapeutic proteins, including monoclonal antibodies, Fc-fusions, bispecifics, and other complex biologics.
German firm Sartorius brings more than 15 years of commercial CLD experience, having completed more than 330 projects, with more than 85 programmes advancing into clinical development and over 10 achieving market approval.
The expanded collaboration reflects both companies’ long-term commitment to supporting biologics innovators with integrated, high-quality development solutions. By building on proven synergies established through multiple successful projects, Sartorius and LFB Biomanufacturing are creating a framework to support the next generation of therapeutic innovation.
